Literature DB >> 15918145

Imaging diagnosis.

Riccardo Lencioni1, Dania Cioni, Clotilde Della Pina, Laura Crocetti, Carlo Bartolozzi.   

Abstract

The diagnosis of hepatocellular carcinoma (HCC) is based on imaging examinations in combination with clinical and laboratory findings. Despite technological advances, imaging cirrhotic patients remains a challenging issue because nonmalignant hepatocellular lesions, such as dysplastic nodules, mimic a small HCC. One of the key pathologic factors for differential diagnosis that is reflected in imaging appearances is the vascular supply to the lesion. It is accepted that imaging techniques may establish the diagnosis of HCC in nodules larger than 2 cm showing characteristic arterial hypervascularization. In lesions ranging from 1 to 2 cm, biopsy is still recommended, although a negative response can never be used to rule out malignancy completely. Although ultrasonography is widely accepted for HCC surveillance, spiral computed tomography (CT) or dynamic magnetic resonance imaging is required for diagnostic confirmation and intrahepatic tumor staging. These examinations have replaced invasive procedures, such as lipiodol CT, but remain relatively insensitive for the detection of tiny HCC lesions and tumor vascular invasion into peripheral portal vein branches.

Entities:  

Mesh:

Year:  2005        PMID: 15918145     DOI: 10.1055/s-2005-871196

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  12 in total

Review 1.  [HCC screening].

Authors:  T Albrecht
Journal:  Radiologe       Date:  2008-01       Impact factor: 0.635

2.  Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma.

Authors:  Vincenzo O Palmieri; Daniela Santovito; Giuseppe Marano; Francesco Minerva; Lara Ricci; Felicia D'Alitto; Giuseppe Angelelli; Giuseppe Palasciano
Journal:  Radiol Med       Date:  2015-01-20       Impact factor: 3.469

3.  Liver Transplantation for a Patient with Hepatocellular Carcinoma with Vascular Invasion and Exceeding Milan Criteria-Happy End Despite it all.

Authors:  R Rozen; Y Menachem; B I Carr; O Shibolet
Journal:  J Gastrointest Cancer       Date:  2018-06

4.  Automatic annotation of radiological observations in liver CT images.

Authors:  Francisco Gimenez; Jiajing Xu; Yi Liu; Tiffany Liu; Christopher Beaulieu; Daniel Rubin; Sandy Napel
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

5.  Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.

Authors:  Pal Kaposi-Novak; Louis Libbrecht; Hyun Goo Woo; Yun-Han Lee; Nathaniel C Sears; Cedric Coulouarn; Elizabeth A Conner; Valentina M Factor; Tania Roskams; Snorri S Thorgeirsson
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

6.  Impact of European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines on the use of contrast agents in liver ultrasound.

Authors:  Riccardo Lencioni
Journal:  Eur Radiol       Date:  2006-02-21       Impact factor: 5.315

7.  Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma.

Authors:  Chun-Ann Chen; Cheng-Kai Lo; Bai-Ling Lin; Eric Sibley; Shiue-Cheng Tang
Journal:  Cancer Biol Ther       Date:  2007-11-21       Impact factor: 4.742

Review 8.  Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media.

Authors:  Carlo Bartolozzi; Laura Crocetti; Riccardo Lencioni; Dania Cioni; Clotilde Della Pina; Daniela Campani
Journal:  Eur Radiol       Date:  2007-02-16       Impact factor: 7.034

9.  Transjugular intravascular ultrasound for the evaluation of hepatic vasculature and parenchyma in patients with chronic liver disease.

Authors:  Andrea De Gottardi; Pierre-Frédéric Keller; Antoine Hadengue; Emile Giostra; Laurent Spahr
Journal:  BMC Res Notes       Date:  2012-01-27

Review 10.  Thermal ablation of hepatocellular carcinoma.

Authors:  Laura Crocetti; Riccardo Lencioni
Journal:  Cancer Imaging       Date:  2008-02-27       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.